Introduction {#s1}
============

Primary cilia are highly conserved organelles essential for developmental signalling pathways and cellular homeostasis. The small G-proteins of the Arl family Arl3, Arl6 and Arl13B have been shown to be important in the trafficking of ciliary proteins and structural integrity of the cilium ([@bib25]). Mutations in Arl proteins or their regulators can lead to cilia dysfunction causing ciliopathies such as Joubert syndrome (JS), Bardet--Biedl syndrome (BBS), or retinitis pigmentosa (RP) ([@bib7]; [@bib11]; [@bib32]). Different ciliopathies are characterized by overlapping phenotypes such as renal cysts, polydactyly, brain malfunction, situs inversus, and vision impairment ([@bib40]). Mutations in Arl6 --the first member of the Arl family found mutated in a human ciliopathy -- cause BBS, whereas mutations in Arl13B lead to JS. JS in particular is characterized by a brain malformation with a characteristic molar tooth sign combined with polydactyly and kidney cysts. Although no mutations in Arl3 have been identified so far in ciliopathies Arl3^(-/-)^ mice exhibit a ciliopathy related phenotype and die by 3 weeks of age ([@bib31]). One of the X-linked RP genes is RP2, which functions as a GTPase activating protein (GAP) specific for Arl3 ([@bib39]).

As most small G-proteins Arl3 cycles between inactive GDP-bound and active GTP-bound forms and in the latter it binds specifically to effectors ([@bib10]). Effectors of Arl3 are the carrier proteins PDE6δ, which binds farnesylated and geranylgeranylated cargo, and Unc119a/b, which binds myristoylated cargo. Binding of activated Arl3 to the cargo-carrier complex induces conformational changes leading to the release of the cargo ([@bib20], [@bib19]; [@bib41]). A close structural homologue of Arl3 is Arl2, which binds to the same set of effectors ([@bib38]). However, while Arl2 and Arl3 can release cargo such as Ras or RheB, only Arl3 is able to release ciliary cargo such as INPP5E, NPHP3, and GNAT-1 ([@bib20]; [@bib37]; [@bib41]). The highly conserved Arl3 − only present in ciliated organisms -- localizes throughout the cell and is enriched in the primary cilium ([@bib2]; [@bib4]; [@bib43]). While RP2 functions as an Arl3 GAP and is thus important for the import of lipidated cargo by recycling Arl3 and its effectors ([@bib33]; [@bib41]; [@bib42]), the guanine nucleotide exchange factor (GEF) that activates Arl3 remains unknown. We had anticipated that in order for Arl3 to mediate cargo release inside cilia, an Arl3-specific GEF should be localized there as well.

Results {#s2}
=======

To identify regulatory proteins of Arl3 we employed a yeast-2-hybrid (Y2H) screen using the fast cycling mutant Arl3△N^D129N^ as bait. The homologous mutation which in Ras was shown to decrease nucleotide and to increase GEF affinity while maintaining its ability to bind to effectors was used by us to identify the GEF for the plant specific ROP proteins ([@bib3]; [@bib12]). Screening a mouse retinal cDNA Y2H library identified several clones growing on selective media. Sequence analysis revealed Arl13B (residues 1--270) in addition to known Arl3 effectors such as PDE6δ and Unc119a. Intriguingly, in a parallel screen with mouse Arl13B^20-278^ as bait Arl3 was found as rescuing clone. The interaction between Arl3 and Arl13B was further verified by directed 1:1 Y2H analysis ([Figure 1A](#fig1){ref-type="fig"}). Arl13B is an unusual Arl protein containing a C-terminal coiled-coil and proline rich region in addition to its G-domain ([Figure 1C](#fig1){ref-type="fig"}). The data show that the interaction is mediated by Arl13B's G-domain and part of the coiled-coil region. To investigate the specificity of the Arl13B-Arl3 interaction we tested the related constructs of Arl2 and Arl6 neither of which enabled growth on selective medium ([Figure 1B](#fig1){ref-type="fig"}).10.7554/eLife.11859.003Figure 1.The interaction between ADP-ribosylation-factor-like (Arl) 13B (Arl13B) and Arl3 was identified in a yeast-2-hybrid (Y2H) screen.(**A**) Y2H interactions between Arl3ΔN D129N -pBD and Arl13B 1---270-pAD and between Arl13B 20- -- 278-pBD and Arl3-pAD. Transformed and mated cells were grown on --Leu --Trp medium. Interaction was verified on high stringency plates (--- Leu --Trp --His --Ade) and with a β-galactosidase filter assay. (**B**) Interaction of Arl13B 1---270-pAD with Arl3ΔN D129N-pBD, Arl2ΔN D128N-pBD and Arl6ΔN D133N-pBD was analyzed on low and high stringency plates. PDE6δ-pAD was used as positive control for Arl3 and Arl2. (**C**) Domain architecture of Arl13B, numbering derived from murine Arl13B (*Mm*: *Mus musculus*).**DOI:** [http://dx.doi.org/10.7554/eLife.11859.003](10.7554/eLife.11859.003)

To verify this interaction in vitro, we tested purified proteins in a glutathione-S-transferase (GST) pull-down assay. Due to better stability and purity of Arl13B from *Chlamydomonas reinhardtii (Cr*) the following experiments were performed with the homologous *Cr*-proteins purified from *Escherichia coli*. We thus prepared *Cr*Arl13B^18---278^ (*Cr*Arl13B from now) analogous to mouse Arl13B^18---278^ used in the Y2H screen and tested its interaction with GST-*Cr*Arl3 loaded with either GDP or GppNHp (a non-hydrolyzable GTP analogue) ([Figure 2A](#fig2){ref-type="fig"}). *Cr*Arl13B·GppNHp but not *Cr*Arl13B·GDP bound to GST---*Cr*Arl3, and binding was slightly stronger to GST-*Cr*Arl3·GDP than to GST-*Cr*Arl3·GppNHp. These data show that the interaction between Arl3 and Arl13B is conserved between mouse and *Chlamydomonas*.10.7554/eLife.11859.004Figure 2.*Cr*Arl13B is the guanine nucleotide exchange factor for *Cr*Arl3.(**A**) Glutathione-S-transferase (GST) pull-down assay with purified *Chlamydomonas reinhardtii* Arl proteins as indicated and described in detail in Material and methods. (**B**) Guanine nucleotide exchange factor (GEF) activity of the indicated concentrations of *Cr*Arl13B^18---278^ for 500 nM *Cr*Arl3·mantGDP. Arrow designates addition of *Cr*Arl13B and excess of unlabeled nucleotide. (**C**) *Cr*Arl13B·GppNHp but not *Cr*Arl6·GppNHp stimulates the nucleotide release of *Cr*Arl3·mantGppNHp. (**D**) *Cr*Arl3·GTP does not accelerate the nucleotide dissociation of *Cr*Arl13B·mantGppNHp. (**E**) GEF activity of 5 µM *Cr*Arl13B^18-278^ loaded with GDP (red), GTP (blue), or GppNHp ((a non-hydrolyzable GTP analogue; yellow). (**F**) Hyperbolic dependence of the observed rate constants for mantGDP release from 500 nM *Cr*Arl3 on *Cr*Arl3B·GTP or *Cr*Arl13B·GDP concentration. Fluorescence changes in time at each concentration of *Cr*Arl13B were fitted to single exponentials, and the resulting rate constants (k~obs~) plotted against GEF concentration. K~obs~ values are summarized in [Table 1](#tbl1){ref-type="table"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.004](10.7554/eLife.11859.004)

Since the rather weak interaction in the pull-down experiments and the nucleotide-independent binding suggested that Arl3 is not an effector for Arl13B, we turned our attention to a possible GEF function. As a ciliary protein Arl13B is a good, albeit, as a G-protein, a very unusual candidate GEF for Arl3. The dissociation of a fluorescent GDP-analogue (mantGDP) from *Cr*Arl3 in the presence of excess of unlabelled GTP was monitored after adding *Cr*Arl13B·GTP. The nucleotide dissociation was strikingly accelerated in the presence of *Cr*Arl13B·GTP and was dependent on the *Cr*Arl13B concentration ([Figure 2B](#fig2){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}). Consistent with features of a typical GEF ([@bib5]) Arl13B did not discriminate whether mantGppNHp or mantGDP was bound to Arl3 and exchanged both nucleotides with the same velocity ([Table 2](#tbl2){ref-type="table"}). As a control *Cr*Arl6 did not stimulate the nucleotide release of *Cr*Arl3 nor did *Cr*Arl3 catalyze that of *Cr*Arl113B ([Figure 2B, C](#fig2){ref-type="fig"}).10.7554/eLife.11859.005Table 1.K~obs~ values from data shown in [Figure 2B and E](#fig2){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.005](10.7554/eLife.11859.005)**Concentration dependency ([Figure 2B](#fig2){ref-type="fig"})K~obs~ (s^-1^)** ± **S.E.***Cr*Arl3 wt intrinsic1.2 × 10^-4^ ± 1 × 10^-5^+ 0.25 µM *Cr*Arl13BGTP1.3 × 10^-3^± 2 × 10^-5^+ 0.5 µM *Cr*Arl13BGTP2.7 × 10^-3^± 3 × 10^-5^+ 5 µM *Cr*Arl13BGTP0.85 × 10^-2^± 1 × 10^-4^**Nucleotide dependency ([Figure 2E](#fig2){ref-type="fig"})K~obs~ (s^-1^)** ± **S.E.***Cr*Arl3 wt intrinsic1.3 × 10^-4^ ± 4 × 10^-6^+ 5 µM *Cr*Arl13BGDP9.0 × 10^-4^ ± 2 × 10^-5^+ 5 µM *Cr*Arl13BGTP0.6 × 10^-2^ ± 8 × 10^-5^+ 5 µM *Cr*Arl13BGNP0.78 × 10^-2^ ± 1 × 10^-4^[^2]10.7554/eLife.11859.006Table 2.k~obs~ values for the nucleotide dissociation of CrArl3·mGDP and CrArl3·mGppNHp in the presence of CrArl13B·GTP.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.006](10.7554/eLife.11859.006)**CrArl3·mGDP vs mGppNHpK~obs~ (s^-1^)** ± **S.E.***Cr*Arl3·mGDP intrinsic1.3 × 10^-4^ ± 2 × 10^-6^*Cr*Arl3·mGDP + 5 µM *Cr*Arl13B·GTP0.84 × 10^-2^ ± 7 × 10^-5^*Cr*Arl3·mGppNHp intrinsic1.3 × 10^-4^ ± 2 × 10^-6^*Cr*Arl3·mGppNHp + 5 µM *Cr*Arl13B·GTP1.0 × 10^-2^ ± 1 × 10^-4^[^3]

We next asked whether the nucleotide-bound state of *Cr*Arl13B affects its GEF activity as suggested by the GST pull-down experiments. *Cr*Arl13B preloaded with GDP, GTP, or GppNHp was used to analyze the exchange activity. At 5 µM GEF, the exchange was about ninefold slower for GDP- than for GTP- and GppNHp-bound *Cr*Arl13B ([Figure 2E](#fig2){ref-type="fig"}). The observed rate constants of mantGDP-dissociation showed a hyperbolic dependence on *Cr*Arl13B concentration, with a maximum release rate of 0.86 × 10^-2^ sec. The K~M~ for the reaction is 1.1 µM for *Cr*Arl13B·GTP and 155 µM for *Cr*Arl13B·GDP ([Figure 2F](#fig2){ref-type="fig"}) showing that *Cr*Arl13B·GTP has a higher affinity than *Cr*Arl13B·GDP. Since the in vitro determined maximal nucleotide release stimulation of 70-fold appears relatively slow but not unusual, it is quite conceivable that additional factors such as the presence of membranes or lipids enhance the GEF activity as shown for the Ras-GEF SOS ([@bib17]) and other GEFs ([@bib6]; [@bib30]). Since Arl3 has a high affinity to membranes ([@bib22]) and Arl13B is palmitoylated ([@bib9]) the reaction between them is thus most likely orchestrated on the ciliary membrane.

Next, we employed x-ray crystallography to elucidate the structural basis for the interaction. We thus co-crystallized *Cr*Arl13B·GppNHp and *Cr*Arl3·GDP in the presence of alkaline phosphatase in order to allow formation of nucleotide free *Cr*Arl3. Since *Cr*Arl13B requires bound nucleotide for stability (and most likely for activity) complex formation could not be performed with nucleotide free Arl3 GEF-substrate. The obtained crystals diffracted to 2.5Å and the structure was solved by molecular replacement showing one complex in the asymmetric unit ([Table 3](#tbl3){ref-type="table"}). Although crystallization was done in the presence of alkaline phosphatase GppNHp was clearly visible in both active sites, suggesting that the structure represents the post-nucleotide-exchange state. The nucleotide dependency of *Cr*Ar13B's GEF activity suggested that switch I and II contribute to the interface. The structure shows indeed that a major part of the interaction is mediated by switch I and II of *Cr*Arl13B which contact *Cr*Arl3 via α4^Arl3^, β6^Arl3^, and α5^Arl3^ located opposite to the nucleotide binding site ([Figure 3A, 3E](#fig3){ref-type="fig"}). Further interactions are between the long α-helix α6^Arl13B^ which makes a 90° turn at residue G189, and α3/ α4^Arl3^. The last 58 residues, predicted to be α-helical, are not visible in the electron density presumably because they are flexible.10.7554/eLife.11859.007Table 3.Data collection and refinement statistics (molecular replacement).**DOI:** [http://dx.doi.org/10.7554/eLife.11859.007](10.7554/eLife.11859.007)*Cr*Arl13B-*Cr*Arl3 (5DI3)**Data collection**Space groupP212121Cell dimensions*a, b, c* (Å)57.10, 68.80, 120.00α, β, γ (°)90.00, 90.00, 90.00Resolution (Å)29.84 -- 2.50 (2.60-2.50)*R*~merge~0.07 (0.68)*I* / σ*I*17.56 (3.26)Completeness (%)99.9 (99.9)Redundancy6.4 (6.8)**Refinement**Resolution (Å)2.50No. reflections16944 (1840)*R*~work~/*R*~free~0.199/0.236No. atoms2995Protein2900Ligand/ion2 Mg^2+^, 2 GMPPNPWater29*B*-factors66Protein66.40Ligand/ion54.30Water55.00R.m.s. deviationsBond lengths (Å)0.005Bond angles (°)1.02[^4]10.7554/eLife.11859.008Figure 3.The *Cr*Arl13B--- *Cr*Arl3 complex.(**A**) The *Cr*Arl13B---*Cr*Arl3 complex structure with Arl13B (green), Arl3 (light blue), Switch I (blue), Switch II (red), GppNHp (a non-hydrolyzable (GTP) analogue; yellow). Residues analogous to Joubert syndrome mutations (R77 and R194) are depicted in cyan. Red asterisks delineate the deletion sites (V202, E212, K219) of *Cr*Arl13 used in the guanine nucleotide exchange factor (GEF) assay below ([Figure 4](#fig4){ref-type="fig"}). Other deletion sites are not resolved in the electron density. Dashed line indicates the 58 C-terminal residues not visible in the structure (**B--D**) Details of the interaction interface. (**C**) Hydrophobic residues located in Switch I and Switch II of *Cr*Arl13B are involved in the interaction with *Cr*Arl3. (**D**) K210 and R213 in α6^Arl13B^ are forming salt bridges with D143^Arl3^ and E103^Arl3^(orange). Coloring as in (**A**). (**E**) Schematic representation of residues located in the interface. Hydrogen bonds between residues are depicted as black dashed line, salt bridges as red dashed line.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.008](10.7554/eLife.11859.008)

To examine the interface we mutated residues within switch I, II, and α6 of *Cr*Arl13B ([Figure 3B--D](#fig3){ref-type="fig"}). Switch I mutant *Cr*Arl13B^F53A^ showed a markedly decreased GEF activity whereas the D46A, F51A, N75A, and Y83A mutants had only a minor effect ([Figure 4A](#fig4){ref-type="fig"}). The charge-reversal mutations K210E/R216E in α6^Arl13B^ as well as D103R and D146R in *Cr*Arl3 show no activity, as expected, whereas a control mutation H154W outside the interface has no effect ([Figure 4B](#fig4){ref-type="fig"}). Since *Cr*Arl13B's analogous Joubert mutation R77Q and to a lesser extent R194C have been shown to impair the conformational stability of switch II ([@bib28]), we next tested the analogous mutants *Cr*Arl13B^R77Q^ and *Cr*Arl13B^R194C^ for their GEF activities. *Cr*Arl13B^R77Q^ displayed a reduced activity in contrast to a very mild effect of *Cr*Arl13B^R194C^ ([Figure 4C](#fig4){ref-type="fig"}).10.7554/eLife.11859.009Figure 4.Mutations in the CrArl13B-CrArl3 interface and Joubert mutations impair guanine nucleotide exchange factor (GEF) activity.(**A**) GEF activity of *Cr*Arl13B^18---\ 278^·GppNHp (a non-hydrolyzable GTP analogue) switch I and II mutants. To *Cr*Arl3 mantGppNHp (500 nM) 5 µM of *Cr*Arl13B·GppNHp constructs and 800 µM unlabeled GppNHp were added. (**B**) GEF assay with *Cr*Arl13B^18-278^·GppNHpand *Cr*Arl3·mantGppNHp carrying charge reversal mutations located in the interface. (**C**) GEF activity of the analogous Joubert syndrome mutants (*Cr*Arl13B^R77Q^, *Cr*Arl13B^R194C^). Same concentrations as in (A). (**D**) GEF assay with *Cr*Arl13B deletion constructs. Boundaries of deletion fragments: △203: 18--202; △213: 18--213; △220: 18--219; △229: 18--228; △233: 18--232. 18--278 are the constructs used for all other GEF assays. K~obs~ values are summarized in [Table 4](#tbl4){ref-type="table"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.009](10.7554/eLife.11859.009)10.7554/eLife.11859.010Table 4.K~obs~ values from data shown in [Figure 4 A--D](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.010](10.7554/eLife.11859.010)***Cr*Arl13B Switch interface mutantsK~obs~ (s^-1^)** ± **S.E.***Cr*Arl3 intrinsic1.4 × 10^-4^ ± 4 × 10^-6^+ 5 µM *Cr*Arl13B **wt** GTP0.91 × 10^-2^ ± 2 × 10^-4^+ 5 µM *Cr*Arl13B **F51A **GTP2.0 × 10^-3^ ± 2 × 10^-5^+ 5 µM *Cr*Arl13B **F53A **GTP4.2 × 10^-4^ ± 2 × 10^-5^+ 5 µM *Cr*Arl13B **Y83A **GTP0.9 × 10^-3^ ± 1 × 10^-5^+ 5 µM *Cr*Arl13B **D46A **GTP4.1 × 10^-3^ ± 8 × 10^-5^+ 5 µM *Cr*Arl13B **N75A **GTP4.4 × 10^-3^ ± 3 × 10^-5^***Cr*Arl13B and *Cr*Arl3 Interface mutantsK~obs~ (s^-1^)** ± **S.E.***Cr*Arl3 **wt** intrinsic1.1 × 10^-4^ ± 1 × 10^-6^*Cr*Arl3 **wt** + 5 µM *Cr*Arl13B **K210E/R216E**1.5 × 10^-4^ ± 1 × 10^-5^*Cr*Arl3 **D103R** + 5 µM *Cr*Arl13B **wt**1.4 × 10^-4^ ± 5 × 10^-6^*Cr*Arl3 **D146R** + 5 µM *Cr*Arl13B **wt**1.4 × 10^-4^ ± 6 × 10^-6^*Cr*Arl3 **wt** + 5 µM *Cr*Arl13B **H154W**0.88 × 10^-2^ ± 2 × 10^-4^*Cr*Arl3 **wt** + 5 µM *Cr*Arl13B **wt**0.85 × 10^-2^ ± 2 × 10^-4^***Cr*Arl13B Deletion constructsK~obs~ (s^-1^)** ± **S.E.***Cr*Arl3 **wt** intrinsic1.0 × 10^-4^ ± 2 × 10^-5^+ 5 µM *Cr*Arl13B **△203**1.0 × 10^-4^ ± 8 × 10^-6^+ 5 µM *Cr*Arl13B **△213**1.0 × 10^-4^ ± 1 × 10^-5^+ 5 µM *Cr*Arl13B **△220**1.1 × 10^-3^ ± 1 × 10^-5^+ 5 µM *Cr*Arl13B **△243**4.5 × 10^-3^ ± 5 × 10^-5^+ 5 µM *Cr*Arl13B **△233**5.0 × 10^-3^ ± 6 × 10^-5^+ 5 µM *Cr*Arl13B **18-278**6.6 × 10^-3^ ± 2 × 10^-4^***Cr*Arl13B Joubert mutantsK~obs~ (s^-1^)** ± **S.E.**CrArl3 intrinsic1.4 × 10^-4^ ± 3 × 10^-6^+ 5 µM CrArl13B **R77Q**5.5 × 10^-4^ ± 1 × 10^-5^+ 5 µM CrArl13B **R194C**2.0 × 10^-3^ ± 2 × 10^-5^+ 5 µM CrArl13B **wt**0.72 × 10^-2^ ± 1 × 10^-4^[^5]

GEF proteins normally act by directly interfering with the nucleotide binding site thereby decreasing nucleotide affinity ([@bib10]). In the crystal structure the nucleotide binding site of *Cr*Arl3 is not directly contacted by *Cr*Arl13B. We were not able to trap the interacting residues presumably due to the presence of nucleotide and/or the flexibility of the interacting residues of Arl13B. Considering the length of the C-terminus required for catalysis (see below) it is however suggestive that the mobile C-terminus of Arl13B is involved in the GEF reaction by contacting the relevant surface of Arl3. To examine the importance of this region for catalysis we prepared deletion constructs with differing length of the α6-helix (see red asterisks in [Figure 3A](#fig3){ref-type="fig"}). Whereas the C-terminal deletion constructs △233(18--232) and △243(18--242) had no effect, a longer deletion to residue 220(18--219) showed a reduced stimulation ([Figure 4D](#fig4){ref-type="fig"}). Finally, the GEF activity of △213(18--212) and △203(18--202) was completely abolished. In support of their importance residues 212--228 are highly conserved among species and we would speculate that these residues contact Arl3 close to the nucleotide binding site.

We next decided to demonstrate the GEF activity of Arl13B in mammalian cells. Therefore we used a stably transfected murine inner medullary collecting duct 3 (IMCD3) cell line and transiently transfected HEK293 cells overexpressing human Arl13B-GFP. To quantify Arl3 activation, Arl3·GTP was affinity-precipitated with the effector GST-PDE6δ ([@bib26]) and analysed by immunoblot. The level of endogenous Arl3·GTP was strikingly increased in cells overexpressing Arl13B compared to control cells ([Figure 5A](#fig5){ref-type="fig"}). Furthermore, the level of GTP-bound Arl3-Flag depended on the Arl13B concentration ([Figure 5B](#fig5){ref-type="fig"}). Consistent with the Y2H data the Arl2·GTP level was not affected by overexpressed Arl13B indicating selectivity for Arl3 ([Figure 5G](#fig5){ref-type="fig"}). Interface mutations in Arl13B which disrupted the in vitro exchange activity were also tested in HEK293 cells. Consistently, cells transfected with Arl13B^K216E/R219E^, Arl13B^Y55A^ or Arl13B^Y85A^ did not markedly increase the Arl3·GTP level ([Figure 5C,D](#fig5){ref-type="fig"}). Intriguingly, the Arl3·GTP level in cells overexpressing the Joubert mutant variants Arl13B^R79Q^ and Arl13B^R200C^ was lower than those expressing Arl13B^wt^. Consistent with the biochemical data the R79Q mutation impaired Arl3 activation was more pronounced than R200C ([Figure 5E,F](#fig5){ref-type="fig"}). Finally, we were able to purify human Arl13B (18--278) from insect cells in reasonable amounts to test its GEF activity. Confirming the conservation of structure and function the human Arl13B also exhibits strong GEF activity for Arl3 ([Figure 6A](#fig6){ref-type="fig"}). The stimulation of the nucleotide release was more efficient compared to *Cr*Arl13B, with a 900fold acceleration at 5 µM. In agreement with the different biological function ([@bib43]), the nucleotide dissociation of Arl2 was not accelerated by Arl13B ([Figure 6B](#fig6){ref-type="fig"}).10.7554/eLife.11859.011Figure 5.Arl13B activates Arl3 in mammalian cells.(**A**) Endogenous Arl3·GTP was affinity-precipitated from Human Embryonic Kidney 293 (HEK293) or murine inner medullary collecting duct 3 (IMCD3) cell lysates using GST-PDE6δ and analyzed as described in Materials and methods. HEK293 cells were transiently transfected with full length Arl13B-GFP(pGLAP5); IMCD3 cells stably expressed the same construct. (**B**) HEK293 cells were transiently transfected with increasing amounts of Arl13B-GFP (0, 1, 3, 6, 12 µg DNA) and constant amounts of Arl3-Flag. Arl3·GTP level determined as in (**A**). (**C**) Arl3-Flag activation in the presence of wildtype and interface mutant Arl13B-GFP was determined as in (**A**) and quantified in (**D**). (**E**) Arl3-Flag activation in the presence Arl13B wt and Joubert syndrome mutants R79Q and R200C. (**F**) Quantification of (**E**). Data is represented as mean ± S.E. (**G**) Arl3-Flag and Arl2-Flag activation in the presence of Arl13B-GFP in HEK293 cells.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.011](10.7554/eLife.11859.011)10.7554/eLife.11859.012Figure 6.The guanine nucleotide exchange factor (GEF) activity of human Arl13B is specific for Arl3.(**A**) GEF activity of human Arl13B^18---278^ (purified from insect cells) for murine Arl3. To 500 nM Arl3·mantGppNHp, 5 µM hsArl13B·GTP and 800 µM GTP were added. k~obs~ (intrinsic): 4 × 10^-4^ s^-1^, k~obs~(Arl13B·GTP): 0,36 s^-1^. (**B**) Human Arl13B·GTP does not accelerate nucleotide dissociation of Arl2·mantGppNHp. k~obs~(intrinsic):1.2 × 10^-2^ s^-1^; k~obs~(Arl13B·GTP): 1.2 × 10^-2^ s^-1^.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.012](10.7554/eLife.11859.012)

Discussion {#s3}
==========

Arl13B has been implicated in a number of ciliary functions ([@bib9]; [@bib18]; [@bib23]; [@bib24]), and its deletion is causing multiple phenotypes such as the lethal hennin mouse mutant or the scorpion zebrafish mutant ([@bib8]; [@bib35]). Here we describe a molecular function for Arl13B acting as GEF for Arl3 whereby the nucleotide state of Arl13B determines its catalytic activity in this activation cascade.

Our results have important implications for the regulation of sorting and transport processes into cilia. It has been shown earlier that Arl3 but not Arl2 can release ciliary cargo from the transport proteins PDE6δ and Unc119 ([@bib20], [@bib19]; [@bib41]). One would predict that Arl3, which is enriched in cilia but also in other microtubule dense structures ([@bib16]; [@bib43]), is only activated inside cilia where Arl13B exclusively resides ([@bib4]; [@bib8]; [@bib14]) in order to avoid release of ciliary prenylated and myristoylated cargo in the cytoplasm, where other cargo such as Ras, RheB, or Src kinases can be released by Arl2. The observation that expression of constitutive active ARL-3 (Q70L/Q72L) in *Lieshmania donovani* and in *Caenorhabditis elegans* resulted in decreased flagellum length and in impaired ciliogenesis might be explained by Arl3-GTP being located all over the cell and by subsequent mistargeting of proteins destined for the cilium ([@bib13]; [@bib24]).

The different subcellular localization of Arl3-GAP and GEF resembles very closely the Ran driven nucleocytoplasmic transport system. Nucleocytoplasmic transport through the nuclear pore is regulated by a Ran gradient across the nuclear pore ([@bib34]). This gradient is regulated by the Ran-GEF RCC1, which is retained inside the nucleus, and by the major form of Ran-GAP, which is located at the exit side of the nuclear pore complex (NPC), by binding to RanBP2 ([@bib27]). Import cargo bound to importins is released from the carrier by Ran·GTP. The export complex formed by the exportin-cargo complex is in turn stabilized by Ran·GTP and dissociated after exit from the NPC and hydrolysis of GTP. Since the Arl3 specific GAP RP2 is absent from primary cilia and enriched in the preciliary region as observed by us and others ([@bib4]; [@bib15]; [@bib16]), we can assume that a similar Arl3·GTP gradient exists across the transition zone and that the Arl3·GTP compartment inside cilia creates a driving force for the transport of prenylated and myristoylated proteins which are allosterically released by Arl3·GTP from their carrier proteins PDE6δ and Unc119a/b (see [Figure 7](#fig7){ref-type="fig"} for a schematic overview). The Ran-GEF RCC1 is retained in the nucleus through its interaction with nucleosomes ([@bib29]). In the case of Arl13B, the N-terminal palmitoylation site, but also the other domains seem to be indispensable for its ciliary localization and retention ([@bib9]; [@bib14]).10.7554/eLife.11859.013Figure 7.The targeting cycle of Arl3 dependent ciliary cargo.In the cilium where Arl13B resides Arl3 gets activated. Through the exclusive localization of Arl13B (Arl3-GEF \[guanine nucleotide exchange factor\]) inside and retinitis pigmentosa 2 (RP2) (Arl3-GAP) outside the cilium an Arl3·GTP gradient is generated across the transition zone. The carriers PDEδ and Unc119a/b bound to ciliary lipidated cargo reach the cilium where Arl3·GTP binds to the carrier proteins and releases the cargo. RP2 --- enriched in the preciliary region -- stimulates the hydrolysis of Arl3·GTP which leads to the dissociation of the carrier proteins from Arl3·GDP.**DOI:** [http://dx.doi.org/10.7554/eLife.11859.013](10.7554/eLife.11859.013)

Since Arl13B's GEF activity is higher in the GTP-bound conformation one may ask if and how the nucleotide status of Arl13B itself is regulated. We have shown before that the intrinsic GTP hydrolysis activity of Arl13B is very low and that the protein active site does not contain a catalytic glutamine residue ([@bib28]). Although we cannot exclude that an Arl13B specific GAP would supply catalytic residues an alternative explanation would be that Arl13B in the absence of GTP hydrolysis is mostly in the GTP-bound form. This does not exclude the existence of an Arl13B-GEF which is presently unknown.

Since both the mutations of the Arl3-GAP RP2 in RP and the Arl3-GEF Arl13B in JSyndrome lead to ciliary defects and ciliopathies, we conclude that the amount of Arl3·GTP needs to be precisely regulated and that both an increase and a decrease of Arl3·GTP is not tolerated for proper function of the cilium.

Material and methods {#s4}
====================

Yeast techniques {#s4-1}
----------------

Mouse retina cDNA library was generated according to \'Mate&Plate\' Library System User Manual (Clonetech), cloned into pGADT7 (short: pAD) and introduced into *Saccharomyces cerevisiae* Y187. Yeast techniques and two-hybrid methods were performed according to the Yeast Protocols Handbook and the Matchmaker GAL4 Two-Hybrid System 3 manual (Clontech) with *S. cerevisiae* AH109. Murine Arl3△N^D129N^ (residues 17--182), Arl6△N^D133N^ (residues 16--186), Arl2△N^D128N^ (residues 17--184) and Arl13B (residue 20--278)were cloned into a Gateway compatible pBD-Gal4 vector (a kind gift from R. Roepman) and *S. cerevisiae* AH109 used as recipient for transformation.

Protein expression and purification {#s4-2}
-----------------------------------

*Cr*Arl13B (UniProt: A8INQ0) and *Cr*Arl3 (UniProt: A8ISN6) were amplified by PCR from a cDNA library from *C. reinhardtii* CC-124 WT(wild- type)mt-\[137c\] \[nit1, nit2, agg1\] (a gift from T. Happe). Respective mutants were generated by site directed mutagenesis PCR. *Cr*Arl3 and *Cr*Arl13B proteins were expressed as GST-fusions and purified as previously described ([@bib28]). *Cr*Arl3 full length was additionally cloned into the pET20 vector to produce C-terminally His-tagged protein. Murine Arl3 full length (UniProt: Q9WUL7) and human Arl2 full length (Uniprot: P36404) in pET20 vectors were already available. Proteins were expressed in BL21DE3 CodonPlus RIL cells at 18°C after induction with 100 µM Isopropyl β-D-1-thiogalactopyranoside (IPTG). Purification of *Cr*Arl3-His, murine Arl3-His and human Arl2-His were conducted as described previously ([@bib39]). Human recombinant His-Arl13B 18--278 was expressed in High-Five insect cells for 66 hr at 27°C after virus infection. Insect cells were lysed in 30 mM Tris (pH7.5), 150 mM NaCl, 5 mM MgCl~2~, 3 mM β-mercaptoethanol, 10% glycerole, and 0.1 mM GTP and Complete protease inhibitor cocktail (Roche) using a Microfluidizer M-110S (Microfluidics). Protein was purified by affinity chromatography using a Talon Superflow column (Clonetech) and size exclusion chromatography. All proteins were stored in buffer M containing 25 mM Tris (pH 7.5) 100 mM NaCl, 5 mM MgCl~2~, 3mM β-mercaptoethanol and 1% glycerole.

Preparation of proteins with defined nucleotide state {#s4-3}
-----------------------------------------------------

Nucleotide exchange to GDP, GTP, or (N-methylanthraniloyl) mantGDP on Arl proteins was performed in the presence of 50mM ethylenediaminetetraacetic acid (EDTA) and a five fold (two fold for mantGxP) excess of nucleotide. After incubation for 2 hrs 100 mM MgCl~2~ was added and the protein separated from the excess of nucleotide by a HiTrap desalting column (GE Healthcare). The nucleotide exchange to GppNHp and mantGppNHp was performed using agarose coupled alkaline phosphatase (AP). AP was removed by centrifugation and excess of nucleotide removed by a desalting column. The amount of protein-bound nucleotide was analyzed by C18 reversed-phase high performance liquid chromatography (HPLC) and quantified with a calibrator detector (Beckman Coulter) and an integrator (Shimadzu).

Pull-down assay with purified protein {#s4-4}
-------------------------------------

Per sample 50 µg GST-*Cr*Arl3 was bound to 50 µl glutathione agarose and washed 2x with 500 µl buffer M. GST-*Cr*Arl3 was incubated in 100 µl buffer M containing 1 mg/ml *Cr*Arl13B^18---278^ (\~37 µM) for 30 min and afterwards washed 2x with 500 µl buffer M. Protein was eluted from beads by addition of sodium dodecyl sulfate (SDS) loading buffer and subsequent boiling and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

Crystallization, data collection and analysis {#s4-5}
---------------------------------------------

*Cr*Arl13B·GppNHp and *Cr*Arl3·GDP (12 mg/ml) were mixed in the presence of AP in the ratio 1:1.2 (Arl3:Arl13B). With the sitting drop/vapour diffusion method crystals appeared in 0.1M Tris pH 8.5, 25% PEG 6000 (PEGII suite, Qiagen) after 3 days. Crystals were fished out of the 96 well plate and flash frozen in a cryo-solution containing the same constituents as the crystallization condition supplemented with 20% glycerol. Data collection was done at the PXII-XS10SA beamline of the Swiss Light Source (SLS) Villingen. Data were indexed and processed with XDS ([@bib21]). Molecular replacement was done with PHASER from the CCP4 package (The CCP4 suite: programs for protein crystallography, 1994). The structure refinement was done using phenix.refine of PHENIX ([@bib1]). Images were generated with PYMOL (<http://www.pymol.org>). Atomic coordinates and structural factors have been deposited in the Protein Data Bank (PDB) under the accession code 5DI3.

Guanine nucleotide exchange assay {#s4-6}
---------------------------------

Nucleotide exchange reactions were performed in buffer M at 20°C. As standard conditions, 500 nM G-protein was incubated and the GEF reaction was started with the addition of a mix Arl13B and an excess of nucleotide. Unless otherwise stated 5 µM GEF was used. Since the species of the in excess added unlabeled G-nucleotide (GDP, GTP, or GppNHP) does not influence the velocity of the GEF reaction, the mix always contained an 800-fold excess of the respective nucleotide which was bound to Arl13B in order to avoid undesirable intrinsic nucleotide exchange of Arl13B. For the intrinsic dissociation the same volume buffer containing unlabeled nucleotide was added. The fluorescence change was monitored using a FluoroMax 4 Spectrofluorometer (Jobin Yvon) with an excitation at 366 nm and emission at 450 nm. Data was fitted to single exponential functions using Grafit5 (Erithacus software) to obtain the k~off~ values. All quantitative parameters were measured two or more times. To ensure that all *Cr*Arl13B mutants are 100% loaded with the same nucleotide, they were exchanged to GppNHp with alkaline phosphatase and the stimulation of the nucleotide release measured for *Cr*Arl3·mantGppNHp. K~M~ and V~max~ were obtained by fitting the data to the Michaelis Menten equation using Grafit5.

Cells lines {#s4-7}
-----------

Mouse renal epithelial Flp-In cells from the inner medullary collecting duct (IMCD3 Flp-In; kind gift from MV Nachury) and HEK293 cells were cultured at 37°C and 5% CO~2~ in Dulbecco's Modified Eagle Medium (DMEM)/F12, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Life technologies) complemented with 10% fetal bovine serum and 1% L-glutamine.

The parental IMCD3 Flp-In cell line contains a stably integrated FRT cassette and was co-transfected with pOG44 coding a FLP recombinase and the appropriate pgLAP5 vector (Addgene) using Lipofectamine 2000 (Life technologies). For selection of successful stable genomic integration the media was supplemented with 200 μg/ml hygromycin (Merck) and expression of the GFP-fusion protein was checked by Western Blot using an anti-GFP antibody (Santa Cruz Biotechnology).

Analysis of Arl13B GEF activity in whole cell lysates {#s4-8}
-----------------------------------------------------

For pull-downs of overexpressed Arl3-Flag 2.5 × 10^6^ HEK293 cells were seeded in 15 cm^2^ dishes 24 hr prior to transfection. Cells were transfected using Polyethylenimine (PEI) at a ratio 3:1 of PEI (µg) : total DNA (µg). Cells were induced to ciliate by withdrawing serum for 30 hr. \~2.5 × 10^7^ cells (1 × 15 cm^2^ dish) were lysed in 1 ml lysis buffer for 30 min at 4°C. For pull-downs of endogenous Arl3 1 × 10^8^ cells (4 × 15 cm^2^ dish) were used. Lysate was cleared by centrifugation and protein concentration normalized. Per sample 50 µg GST-PDE6δ was coupled to 50 µl glutathione agarose which was incubated with cleared lysates for 45 min at 4°C. Cleared lysate was removed and beads washed 2x with 500 µl buffer M. Samples were eluted with 1 × SDS-loading buffer. For the detection of affinity-precipitated endogenous Arl3 an anti-Arl3 antibody (Novus Biologicals) was used, and in case of Arl3-Flag an anti-Flag antibody (Thermo Scientific) was used. Expression of Arl13B-GFP was checked using an anti-GFP antibody (Santa Cruz Biotechnology) and antibody against S-peptide, which is located between Arl13B and GFP in pGLAP5. The level of Arl3·GTP was quantified using ImageJ. Experiments were repeated two or more times.
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Thank you for submitting your work entitled \"A G-protein activation cascade from Arl13b to Arl3 and implications for ciliary targeting of lipidated proteins\" for consideration by *eLife*. Your article has been reviewed by Richard Aldrich (Senior editor), David Clapham (Reviewing editor), and three peer reviewers. One of the three reviewers, DickGörlich (reviewer\# 3), has agreed to reveal his identity.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Gotthardt et al. identifies Arl13b as the GEF for Arl3 and describes a comprehensive interaction, activity and structural investigation of the two proteins. Arl13b is a G-protein residing in the cilium and is often used as a marker to visualize cilia. However, the molecular function of Arl13b is not known. Arl3 is another G-protein that is required for proper cilium function and is specifically involved in the transport of lipidated cargo proteins to the cilium. The authors of the manuscript carried out yeast-2-hybrid analysis using a mouse retinal cDNA library whereby they identified an interaction between Arl3 and Arl13b. Using recombinantly purified *Chlamydomonas* proteins, for which the solubility was apparently better, it is convincingly shown that Arl13b is indeed a GEF for Arl3. The crystal structure of the complex is also presented and numerous structure-based or disease causing mutations are tested for their impact on GEF activity. The crystal structure represents the post-catalytic state of the complex (Arl3 in a GTP-analog bound state) and thus does not reveal any direct mechanistic insights into the GEF mechanism. The structure does however reveal the molecular basis for Arl3-Arl13b interaction and suggest that residues following a coiled-coil region of Arl13b may be responsible for interaction with the Arl3 G-site, a notion that is confirmed using truncated Arl13b protein in GEF assays. Finally, the manuscript presents the impact of over-expression of WT or mutant Arl13b on the level of Arl3-GTP in different human cell lines and also demonstrates GEF activity for the human proteins pointing to an evolutionarily conserved mechanism.

Essential revision:

1\) [Figure 2](#fig2){ref-type="fig"} and corresponding legend are confusing. The legend for C) refers to a red, blue and yellow curve although the curves in panel C) are actually green, blue and yellow. It appears that the figure legends for panel C and E have been swapped. Similarly it appears that the legend for panel D and F have been swapped.

Minor points:

1\) [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}: please state whether the numbers following plus/minus standard deviations or standard errors in the legend.

2\) Explain the irregularity of the GEF curve in [Figure 4A](#fig4){ref-type="fig"} (Y83A, grey curve)? Also, units for the x-axis are missing for [Figure 4A](#fig4){ref-type="fig"}.

3\) The authors state: "In the crystal structure, the nucleotide binding site of *Cr*Arl3 is not directly contacted by *Cr*Arl13B, and cannot be trapped presumably due to the presence of nucleotide and/or its flexibility". This is quite a bold statement. Maybe change to: "we were not able to trap...".

4\) This sentence needs clarification or rephrasing: "Intriguingly, the Arl3·GTP level of cells overexpressing the Joubert mutant variants Arl13B^R79Q^ and Arl13B^R200C^ was less increased consistent with the biochemical data whereby the effect of R79Q was more drastic ([Figure 5E,F](#fig5){ref-type="fig"})".

5\) [Table 3](#tbl3){ref-type="table"} appears to have a typo for R.m.s.d. for bond length. The number should probably be 0.005̄A instead of 0.0005A. If not then the structure was refined with too tight geometry restraints (even for 0.005A one could argue that it would make sense to loosen the restraints a bit).

6\) One reviewer suggested a cartoon illustrating a ciliary targeting cycle.

7\) There is an obvious parallel to the RanGTP gradient model for importin and exportin function. Right now, this is just mentioned in passing, late in the Discussion, and not in sufficient detail to grasp the concept. This could be expanded and linked to references. The rationale of the story would become clearer if the Ran-gradient concept were explained first.

8\) The main text should start with a coherent introduction. Right now, the introductory paragraph is far too minimalistic for any reader who is not absolutely acquainted with the ciliary targeting field. For example, it should be explained which proteins are targeted, how Arl3 mediates cargo release, how the Arl3 GAP functions in ciliary protein targeting, and why the localisation of this GAP is important. And it should be explained what a ciliopathy phenotype actually is.

These points can be answered in the Discussion:

9\) Arl13 itself is a GTP-binding protein, and the authors show that its GTP-bound form has a higher Arl3-GEF activity. How is the nucleotide-bound state of Arl13 controlled? Has Arl3 any effect?

10\) It is a bit odd that Arl3 (in the nucleotide exchange intermediate) crystallised with a bound GppNp. Did the authors also try to co-crystallise the D129N mutant? And does this mutant indeed have a higher affinity for Arl13B?
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Author response

Essential revision:

*1) [Figure 2](#fig2){ref-type="fig"} and corresponding legend are confusing. The legend for C) refers to a red, blue and yellow curve although the curves in panel C) are actually green, blue and yellow. It appears that the figure legends for panel C and E have been swapped. Similarly it appears that the legend for panel D and F have been swapped.*

This has been corrected.

*Minor points:*

*1) [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"} and [4](#fig4){ref-type="fig"}: please state whether the numbers following plus/minus standard deviations or standard errors in the legend.*

Plus/minus standard errors were added to the figures and tables where required.

*2) Explain the irregularity of the GEF curve in [Figure 4A](#fig4){ref-type="fig"} (Y83A, grey curve)? Also, units for the x-axis are missing for [Figure 4A](#fig4){ref-type="fig"}.*

Units for the axis of [Figure 4A](#fig4){ref-type="fig"} were fixed. The irregularities in Y83A are an instrumental artefact. All Arl13B mutants behaved well during purification and nucleotide exchange, so that we do not think that the irregularities are derived from instable protein. In the other measurement we did not observe the variations anymore. We exchanged the Y83A curve in [Figure 4A](#fig4){ref-type="fig"}.

*3) The authors state: "In the crystal structure, the nucleotide binding site of* Cr*Arl3 is not directly contacted by* Cr*Arl13B, and cannot be trapped presumably due to the presence of nucleotide and/or its flexibility". This is quite a bold statement. Maybe change to: "we were not able to trap...".*

We changed the sentence accordingly.

4\) This sentence needs clarification or rephrasing: "Intriguingly, the Arl3·GTP level of cells overexpressing the Joubert mutant variants Arl13B^R79Q^ and Arl13B^R200C^ was less increased consistent with the biochemical data whereby the effect of R79Q was more drastic ([Figure 5E,F](#fig5){ref-type="fig"})".

The sentence was rephrased.

5\) [Table 3](#tbl3){ref-type="table"} appears to have a typo for R.m.s.d. for bond length. The number should probably be 0.005̄A instead of 0.0005A. If not then the structure was refined with too tight geometry restraints (even for 0.005A one could argue that it would make sense to loosen the restraints a bit).

[Table 3](#tbl3){ref-type="table"} was corrected.

*6) One reviewer suggested a cartoon illustrating a ciliary targeting cycle.*

We included a cartoon showing the Arl3-dependent ciliary targeting cycle.

*7) There is an obvious parallel to the RanGTP gradient model for importin and exportin function. Right now, this is just mentioned in passing, late in the Discussion, and not in sufficient detail to grasp the concept. This could be expanded and linked to references. The rationale of the story would become clearer if the Ran-gradient concept were explained first.*

*8) The main text should start with a coherent introduction. Right now, the introductory paragraph is far too minimalistic for any reader who is not absolutely acquainted with the ciliary targeting field. For example, it should be explained which proteins are targeted, how Arl3 mediates cargo release, how the Arl3 GAP functions in ciliary protein targeting, and why the localisation of this GAP is important. And it should be explained what a ciliopathy phenotype actually is.*

The Discussion and Introduction were extended.

These points can be answered in the Discussion:

*9) Arl13 itself is a GTP-binding protein, and the authors show that its GTP-bound form has a higher Arl3-GEF activity. How is the nucleotide-bound state of Arl13 controlled? Has Arl3 any effect?*

We included a part about the regulation of Arl13B in the Discussion. We analysed if Arl3 has an effect on the nucleotide dissociation of Arl13B ([Figure 2D](#fig2){ref-type="fig"}), which was not the case. In [Figure 2D](#fig2){ref-type="fig"} you can see that the nucleotide dissociation of GTP from Arl13B is slower in the presence of Arl3, most likely due to binding to Arl3. Additionally, we checked if the presence of Arl3 stimulates the GTP hydrolysis of Arl13B. This was not the case either.

*10) It is a bit odd that Arl3 (in the nucleotide exchange intermediate) crystallised with a bound GppNp. Did the authors also try to co-crystallise the D129N mutant? And does this mutant indeed have a higher affinity for Arl13B?*

We tried to purify CrArl3 D129N which unfortunately failed because the protein precipitated during the purification steps. Low affinity mutants of small G proteins very often are unstable after bacterial expression. We also tried to purify the complex of Arl13B-Arl3D129N, but we weren't able to purify a stable complex either.

[^1]: These authors contributed equally to this work.

[^2]: K~obs~ values ± standard error (S.E.) were determined by fitting the data to single exponential functions. .

[^3]: k~obs~ rates determined from GEF assays with 0.5 µM *Cr*Arl3 loaded with either mantGDP or mantGppNHp in the presence of 5 µM *Cr*Arl13B^18---278·^GTP and 800 µM unlabeled nucleotide.

[^4]: \*Values in parentheses are for highest-resolution shell.

[^5]: K~obs~ values were determined by fitting the data ([Figure 4 A-D](#fig4){ref-type="fig"}) to single exponential functions. If not stated otherwise *Cr*Arl13B 18-278 is used for the measurements.
